Results 131 to 140 of about 695,446 (323)

Tick cysteine protease inhibitors suppress immune responses in mannan-induced psoriasis-like inflammation

Frontiers in Immunology
Protease inhibitors regulate various biological processes and prevent host tissue/organ damage. Specific inhibition/regulation of proteases is clinically valuable for treating several diseases.
Huimei Wu, Huimei Wu, Mohamed Amine Jmel, Jinwei Chai, Maolin Tian, Xueqing Xu, Xueqing Xu, Yuan Hui, Kutty Selva Nandakumar, Kutty Selva Nandakumar, Michail Kotsyfakis, Michail Kotsyfakis   +11 more
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Protease Inhibitors

Journal of the Japanese Association for Infectious Diseases, 2005
  +6 more sources

Interaction of rat liver lysosomal membranes with actin. [PDF]

, 1984
Membranes were prepared from lysosomes purified 80-fold by centrifugation in a discontinuous metrizamide gradient. When salt-washed membranes were combined with rabbit muscle actin, an increase in viscosity could be measured using a falling ball ...
Bame, KJ, Mehrabian, M, Rome, LH
core  

Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping [PDF]

, 2013
Sophie Vallet, Sylvie Larrat, Syria Laperche, Hélène Le Guillou‐Guillemette, Florence Abravanel, Françoise Bouchardeau, Adeline Pivert, Cécile Henquell, Audrey Mirand, Elisabeth André‐Garnier, Valérie Giordanengo, Gisèle Lagathu, Vincent Thibault, Caroline Scholtès, Évelyne Schvoerer, Catherine Gaudy‐Graffin, Sarah Maylin, Pascale Trimoulet, Étienne Brochot, Sébastien Hantz, Joël Gozlan, Anne‐Marie Roque‐Afonso, Patrick Soussan, Jean‐Christophe Plantier, Charlotte Charpentier, Stéphane Chevaliez, Philippe Colson, Vincent Mackiewicz, Lina Aguilera Munoz, S. Rosec, S. Gouriou, Nelly Magnat, Françoise Lunel‐Fabiani, Jacques Izopet, Patrice Morand, Christopher Payan, Jean–Michel Pawlotsky   +36 more
openalex   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Leveraging peptide substrate libraries to design inhibitors of bacterial Lon protease [PDF]

, 2019
Brett M. Babin, Paulina Kasperkiewicz, Tomasz Janiszewski, Euna Yoo, Marcin Drąg, Matthew Bogyo   +5 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source